|
Antitumor activity of trabectedin and lurbinectedin in germline BRCA2 carriers with metastatic breast cancer (MBC) as compared to BRCA1 carriers: Analysis of two phase II trials. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbvie |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Vertex |
Research Funding - Abbvie (Inst); Biomarin (Inst); Calithera Biosciences (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); PharmaMar (Inst); Sanofi (Inst); Vertex (Inst) |
Travel, Accommodations, Expenses - Biomarin; Myriad Genetics; PharmaMar |
| |
|
Consulting or Advisory Role - Abbvie; Merrimack; Myriad Genetics; PharmaMar |
Research Funding - Abbvie; Genentech; OncoPep; PharmaMar |
Travel, Accommodations, Expenses - Myriad Genetics |
| |
|
|
Stock and Other Ownership Interests - PharmaMar |
| |
|
|
Stock and Other Ownership Interests - PharmaMar |
| |
|
|
Stock and Other Ownership Interests - PharmaMar |
| |
|
|
Stock and Other Ownership Interests - PharmaMar |
| |
|
No Relationships to Disclose |